Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ROTEM-guided Transfusion Protocol in Attempt to Reduce Blood Transfusions in Major Oncological Surgery (ROTEM-SUR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03993977
Recruitment Status : Withdrawn (Due to changes in the surgical technique, no potential subjects anymore)
First Posted : June 21, 2019
Last Update Posted : December 16, 2020
Sponsor:
Information provided by (Responsible Party):
Tampere University Hospital

Brief Summary:
Need for perioperative blood transfusion is still high in certain types of oncological abdominal surgery. Allogeneic blood transfusion may be detrimental in cancer patients undergoing a potentially curative resection of malignant tumor, although the detailed mechanism of this effect is still under debate. We plan to evaluate whether a new, rotational thromboelastography-guided algorithm (ROTEM) to guide hemostatic resuscitation intra-operatively decreases the use of allogeneic blood products, the total amount of bleeding, transfusion related side effects, thromboembolic complications and costs. Its effect on each patient's post-operative hemostatic profile is also measured. 60 patients having a potentially curative pancreaticoduodenectomy (or resection of cauda of pancreas), total removal or partial resection of kidney and open radical cystectomy are recruited when an active blood loss of more than 1500 ml is estimated and/or measured and are randomized into two groups: one will be treated conventionally, ie. using massive transfusion protocol (MTP) if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm.

Condition or disease Intervention/treatment Phase
Blood Loss, Surgical Blood Loss Requiring Transfusion Coagulation Defect; Acquired Diagnostic Test: Rotational thromboelastometry Other: Conventional treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 60 patients having a potentially curative abdomino-oncological surgery and reaching an active blood loss of more than 1500 ml are randomized into two groups. One will be treated conventionally, ie. using MTP if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm. Randomization (ratio 1:1 in blocks of 10) between the two groups will be done beforehand. Each paper containing the treatment protocol in question will be put into a closed envelope. The envelopes are numbered from 1 to 60 and are placed in a box in the operative department.
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Participants do not know which group he/she is randomized into. They are under general anaesthesia, thus not knowing which protocol is used. When assessing outcomes, two groups are labeled only by number: the assessor does not know which arm is number 1 or 2 until whole data is analyzed.
Primary Purpose: Treatment
Official Title: ROTEM-guided Transfusion Protocol Versus Standard Care in Attempt to Reduce Blood Transfusions in Potentially Curative Major Abdominal and Urological Oncological Surgery
Estimated Study Start Date : May 1, 2020
Actual Primary Completion Date : October 13, 2020
Actual Study Completion Date : October 13, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ROTEM-arm
Treatment of significant blood loss using point-of-care testing of whole blood viscoelasticity (ROTEM) monitoring coagulopathy or hyperfibrinolysis.
Diagnostic Test: Rotational thromboelastometry
ROTEM-guided protocol of hemostatic resuscitation
Other Name: ROTEM

Active Comparator: Control-arm
Treatment of significant blood loss conventionally, ie. using massive transfusion protocol if necessary, clinical judgement and conventional coagulation tests, such as prothrombin time (as international normalized ratio, INR), activated partial thrombin time (APTT), fibrinogen in plasma (Clauss method).
Other: Conventional treatment
Clinical judgement and conventional coagulation tests




Primary Outcome Measures :
  1. Number of transfused red blood cell (RBC) units [ Time Frame: 24 hours after beginning of surgery ]
    Red blood cell units transfused per patient during operation or up to 24 hours after beginning of surgery


Secondary Outcome Measures :
  1. Intensive care admissions [ Time Frame: 30 days after surgery ]
    Number of patients admitted to intensive care or high dependency, if this is considered associating with the surgery

  2. Length of hospital stay [ Time Frame: 30 days after surgery ]
    Number of days patient is in hospital immediately after surgery

  3. Transfusion-related side effects [ Time Frame: 30 days after surgery ]
    Any side-effect considered or suspected originating from blood product transfusion

  4. Thromboembolic events [ Time Frame: 30 days after surgery ]
    Clinically diagnosed deep vein thrombosis, pulmonary embolism, stroke or other thromboembolic event


Other Outcome Measures:
  1. Signs of altered coagulation [ Time Frame: 12-24 hours after surgery ]
    Possible signs hypercoagulopathy in thromboelastometry: EXTEM value of more than 72 mm



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 18, radical cystectomy, total or partial nephrectomy for malignant disease or pancreaticoduodenectomy planned and estimated intraoperative hemorrhage over 1500ml, written and informed consent

Exclusion Criteria:

  • Known hemophilia or von Willebrandt's disease (treatment planned beforehand in collaboration with haematologist), unacceptance of allogeneic blood products (jehovah's witnesses).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03993977


Locations
Layout table for location information
Finland
Tampere University Hospital
Tampere, Finland, 33560
Sponsors and Collaborators
Tampere University Hospital
Investigators
Layout table for investigator information
Study Director: Anne Kuitunen, MD, PhD Deputy chief physician
Layout table for additonal information
Responsible Party: Tampere University Hospital
ClinicalTrials.gov Identifier: NCT03993977    
Other Study ID Numbers: ETL R17025
First Posted: June 21, 2019    Key Record Dates
Last Update Posted: December 16, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tampere University Hospital:
ROTEM
thromboelastometry
blood transfusion
cancer
surgery
abdominal
oncological
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemostatic Disorders
Blood Coagulation Disorders
Hemorrhage
Blood Loss, Surgical
Pathologic Processes
Intraoperative Complications
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders